Interleukin 3 is a 26-28 kD glycoprotein produced by antigen-and lectinstimulated T lymphocytes, and constitutively released in culture by the mouse tumor cell line WEHI-3 (i). Ik-3 was purified to homogeneity from material obtained from WEHI-3 cells (2), and the gene encoding it was isolated (3, 4).
Dr. J. McKearn (Basel Institute for Immunology). T cells from BALB/c mice were obtained by passing spleen cells through nylon wool columns (11) , and IgM-bearing spleen B lymphocytes were isolated by panning, as described (10) . Cell suspensions from fetal liver and bone marrow were prepared as described before (10, 12) . Cells from thymuses and lymph nodes (mesenteric) were obtained as recommended by Mishell and Shiigi (13) . Spleen cells (2 × 106 cells/ml) were activated by Con A (2 t~g/ml; Pharmacia Fine Chemicals, Upssala, Sweden) or LPS (50 #g/ml; Difco Laboratories, Detroit, MI) at 37°C for 48 h in 50 ml tissue culture flasks (A/S Nunc, Roskilde, Denmark).
Cytokines. rIL-2 (14) was a gift of Dr. W. Fiefs and Biogen (Geneva, Switzerland), mouse rIL-3 (3) was a gift of Dr. T. Yokota and DNAX (Palo Alto, CA), purified IL-1 and purified colony stimulating factor of granulocytes and macrophages (GM-CSF) 1 were purchased from Genzyme (Suffolk, England). B cell maturation factor (BMF), constitutively secreted by the LD1 T helper line (15) was prepared as follows: 2 X 106 LD1 cells in 1 ml of culture medium (Iscove's Dulbecco-modified medium [IDMM] plus 2% heatinactivated human AB serum, gentamycin (50 t~g]ml), and 2-ME (5 x 10 -5 M) were incubated at 37°C for 3-4 d. The supernatants were collected, filtered (0.2 #m Acrodisc filters), and assayed for BMF activity as detailed below. Aliquots of active supernatants were taken and stored at -20°C. They did not contain detectable IL-1, IL-2, IFN-% or B cell growth factor (BCGF) activities. Supernatant from spleen cells (BALB]c and CBA/J mice) stimulated with Con A (Con A-Sup) were prepared as described before (15) . Assays for Cytokine Activity. IL-1 was tested by its capacity of promoting the production i.p. into a BALB/c mouse, and this procedure repeated twice at intervals of 3 wk between each injection. 4 d after the last boost, splenocytes were isolated and fused with the HATsensitive non-Ig secretor myeloma PAI-O (a gift of Dr. H. Jacot, Hoffmann-La Roche, Basel, Switzerland) at a ratio of 5:1 using a 50% (wt/vol) solution of PEG (4,000 tool wt). The cells were distributed in 96 microplate wells in a final volume of 200 ~1 of HAT selective medium. 10-15 d later, wells containing growing hybridomas were screened for reactivity against IL-3-sensitive clones by an indirect radioimmunobinding assay using 1~SI-labelled F(ab)2 rabbit anti-total mouse Ig (New England Nuclear, Boston, MA) as second antibody. 5 out of 1,340 wells screened were found to specifically react against IL-3-sensitive cells. Two of these five hybridomas are described here; hybridomas CC11 and CB5 were cloned and recloned by limiting dilution, (0.5 cells/microplate well) and are maintained in culture medium in tissue culture flasks. The type of Ig secreted by CC11 and CB5 hybridomas was identified by double-diffusing agar gels using goat antimouse IgG1, IgG2, IgG3, and IgM antisera (Nordic, Tilburg, the Netherlands). CC11
I Abbreviations used in this paper: BMF, B cell maturation factor; Con A-Sup, supernatant of spleen cells stimulated with Con A; GM-CSF, colony-stimulating factor of granulocytes and macrophages; IDMM, Iscove's Dulbecco-modified medium.
and CB5 hybridomas secrete mouse IgG2, which bind to protein A, and fix rabbit complement. CCI 1 and CB5 mAb were purified from hybridoma culture supernatants by protein A-Sepharose column chromatography (Pharmacia Fine Chemicals). They were dialyzed, filtered, and stored at -70°C until used.
Other Antibodies. The following mAb were used in the form of hybridoma culture supernatants: M 1/42 (18) antibody reactive with It-2 antigens of all haplotypes; 34-2-12 S (I 9) antibody against H-2-D d. Both hybridomas were obtained from the American Type Culture Collection. 14.8 (20) antibody against the B-220 molecule was kindly provided by Dr. P. Kincade (Oklahoma Medical Center, OK).
Purification of CCll/CB5 + and CCtl/CB5-Bone Marrow Cells. Bone marrow celt suspensions were prepared from femurs and tibia of BALB/c mice as detailed elsewhere (12) . The cells were washed two times in balanced salt solution (BSS) and resuspended in separation medium (IDMM with 5% FCS, gentamycin, and 2-ME) at 6 X 107 cells in 3 ml. The cells (3 ml of cell suspension) in 50 ml conical plastic tubes (2070 F; Falcon Labware, Oxnard, CA) were exposed to CC11 or CB5 mAb (70 ug/tube) at 4°C for 30 rain. The tubes were centrifuged (5 rain, 800 g), and the supernatants were discarded. The cells in the pellet were resuspended by gently shaking the tubes, and they were mixed with a suspension of protein A-coupled SRBC (final dilution 1:25) in a final volume of 5-6 m l of separation medium. The tubes were spun (5 rain, 800 g), and incubated at 4 °C for 45-60 min. The pellet was gently resuspended with wide-bore Pasteur pipettes and layered over a 3-ml Ficoll-Hypaque gradient contained in round-bottom plastic tubes (2057; Falcon Labware), and the tubes were centrifuged at 4°C (40 rain, 1,100 g). Nonrosette forming cells were collected from the interphase, and rosette-forming cells in the pellet were resuspended gently in separation medium and centrifuged again over FicollHypaque gradients as indicated above. Rosette-forming cells in the pellet of the second gradient were collected, the erythrocytes were iysed with ammonium chloride-Tris buffer, and the remaining viable cells were washed in separation medium and resuspended in culture medium (see above) at desired concentrations. The non-rosette forming cells obtained in the first gradient were treated with CCI 1 or CB5 mAb (40 ~g/ml, depending on which antibody was used in the separation) plus low-toxicity rabbit complement (final dilution, 1:12; Cedarlane Laboratories) to further deplete these cells of CC11/CB5 + cells. The cells were washed and resuspended in culture medium at desired concentrations. Both populations were then cultured at 37°C for 12-18 h to allow both shedding of the antibodies and reexpression of the CC1 I/CB5 glycoprotein.
Purity of the cell populations was determined by immunofluorescence microscopy (200-300 cells analyzed) using both CC11 and CB5 mAb as first antibody, and FITCconjugated F(ab')2 rabbit anti-mouse IgG antibody as second antibody. Non-rosette forming cells contained ~<1-4% CC11/CB5 ÷ cells, and rosette-forming cells had 96-98.7% CC11/CB5 ÷ cells. The experiment described in Fig. 5 was conducted with a preparation of cells where we could obtain highly purified CC11 + (I>98.7% CC11/CB5 ÷ cells) and CC 11-(~< 1% CC 11/CB5 + ceils) cell populations. CC 11/CB5 + and CC 11/CB5-cells (5 × 104 cells/well) were placed in round-bottom microplate wells in the presence or absence of the following stimuli: purified IL-1 (20 U/ml), rIL-2 (20 U/ml), rlL-3 (20 U/ml), or Con A-Sup (final concentration 25%) in a final volume of 200 ul of cultur~ medium per well. The cultures in triplicate were incubated at 37°C for 48 h. Cell proliferation was determined by [3H]thymidine uptake (1/~Ci/well) during the last 8 h of the culture period.
Immunofluorescence Staining and Flow Fluorometry. The different types of cells (3-5 x 10s), harvested in logarithmic phase of growth, were incubated with purified CCI 1 and CB5 mAb (15 ug/tube), or with the M1/42 rat anti-H-2 antigen antibody (positive control) at 4 °C for 30 min. The cells were washed once and resuspended in buffer (PBS plus 0.1% BSA plus 0.1% NaNs) containing an appropriate dilution of FITC-conjugated F(ab')~ rabbit anti-mouse IgG or rabbit anti-rat IgG at 4°C for 30 rain. Negative controls were cells incubated in second labelled antibody only. The cells were washed twice in buffer, and a third time in buffer containing propidium iodine to exclude dead cells from anaTysis.
Fluorescence intensity was measured by a FACS-II (Beckton Dickinson Immunocytometry
Systems, Mountain View, CA) equipped with an argon ion laser. Data were collected from 104 ceils analyzed in 1024 channels using logarithmic amplification of fluorescence emitted by single viable cells.
Effect of CC11 and CB5 mAb on Various Cellular Functions. The effects of CC11 and CB5 mAb on the action of IL-1 (20 U/ml), IL-2 (20 U/ml), IL-3 (1-100 U/ml), BMF (final concentrations 10-40%); proliferative responses to Con A, PWM, and LPS; and on maturation of spleen B cells into antibody-secreting cells driven by LPS were studied by adding different concentrations of CC 11 and CB5 mAb (0.1-40 #g/ml) or control mAb M 1/42, 14.8 (final concentrations 10-40%) at the beginning of the assays, carried out in triplicate as detailed above.
The capacity of IL-3 of modulating the expression of the CC11/CB5 glycoprotein on the cell membrane was studied as follows: Bc/Bm 11 IL-3-sensitive cloned cells in logarithmic phase of growth were incubated (2.5 × 105 cells in 12 × 75-mm round-bottom plastic tube [2054; Falcon Labware]) in the presence or absence of 150 U of IL-3, IL-2, or GM-CSF at 37°C for 6-8 h. The tubes were centrifuged (5 min, 800g), the supernatants were discarded, and the cells were tested for the presence of CC 11, CB5, and class I MHC antigens (control) by immunofluorescence staining and flow cytometry as detailed above.
Cell Labelling and lmmunoprecipitation. Ceils (2 × 107, viability >90%) were extensively washed with PBS, 1 mM CaC12, and suspended in 0.4 ml of the same buffer with 0.1 ml 200 mM sodium phosphate, pH 7.2, in a tube coated with 100 #g Iodogen (Pierce Chemical Co., Rockford, IL). After addition of 1 mCi carrier-free Nal~I (100 mCi/ml; Amersham Corp.) the tube was shaken gently for 15 min on ice. The cells were pelleted at 3,000 g for 10 s, and washed three times with 1 ml cold PBS, 1 mM CaCI2. The pellet was lysed in 1 ml lysis buffer, pH 7.2, containing 1% NP-40 (Fluka Biochemicals, Switzerland), 0.1% sodium deoxycholate, 20 mM sodium phosphate, 0.14 M sodium chloride, 1 mM PMSF, 0.3 TIU/ml aprotinin (Sigma Chemical Co., St. Louis, MO) and 0.05% Ovalbumin. After standing for 3 rain at 0°C, the lysate was spun 3 min at 12,000 g, and the supernatant was further cleared at 50,000 g for 1 h.
Antibody was coupled to CNBr-activated Sepharose 4 B (Pharmacia Fine Chemicals) according to the manufacturers recommendations. In a typical experiment, 25 tA antibody-Sepharose beads were incubated with 0.5 ml lysate in a vial, rolling over end for 1 h at 4 °C. The beads were washed, with change of tubes, once with 1 ml and four times with 5 ml lysis buffer without the protease inhibitors. The final wash was with 3 ml of 20 mM Tris-HCI, pH 8.0.
Electrophoresis and Enzyme Treatment. Antigen was eluted from the Sepharose beads with 1% SDS sample buffer containing either 1% 2-ME or 4 mg/ml iodoacetamide, and boiled 3 min before SDS-PAGE. Two-dimensional electrophoresis was performed according to the procedure of O'Farrell (21), after eluting the antigen with 9 M urea, 1% 2-ME, 2% ampholines, pI 9-11 (LKB, Br~mma, Sweden), and 2% NP-40. For treatment with endoglycosidase F, the beads were boiled 3 min in 50 ~1 sample buffer containing 0.5% SDS, 1% 2-ME, 10 mM sodium EDTA, 10 mM Tris-HC1, pH 8.8.5 t~l 10% NP-40 and 5 #1 endoglycosidase F (kindly supplied by Dr. J. Kaufman, Basel Institute for Immunology) with 1 mM PMSF and 0.3 TIU/ml aprotinin were added and incubated 3 h at 37°C. Under these conditions, the proteolysis observed with 12~I-BSA as substrate was negligible. 15 ~1 of a solution containing 10% SDS, 40% 2-ME, and 50% glycerol were added, and the samples were boiled again befbre SDS-PAGE. [14C]Methylated proteins (Amersham Corp.) were used as molecular weight markers.
Results
The hybridomas CC11 and CB5 were obtained by fusing splenocytes from a BALB/c mouse (repeatedly immunized with IL-3R ÷ Ea3 cells) with the HATsensitive myeloma PAI-O. Both CCll and CB5 hybridomas secrete mouse IgG2bK, which bind to protein A and which fix rabbit complement. All the experiments described below were carried out with purified CC11 and CB5 mAb.
Specificity. The specificity of CC 11 and CB5 mAb was defined by testing their reactivity against a large panel of normal cells, growth factor-dependent lines and tumor cells representing various lineages by both immunofluorescence staining and flow fluorometry and indirect radioimmunobinding assays. All 18 IL-3-dependent mouse cell lines derived from spleen, bone marrow, and fetal liver tested, the pre-B cell lymphomas (70Z/3, 18.81, Raw 8.1) studied and the mastocytoma P-815 carried both CC 11 and CB5 antigens on their cell membrane. The following type of cells were negative for CC 11 and CB5 antigens: thymomas (EL-4, BW5147), IL-2-dependent T cell lines (CTLL, CFL 1), the cytolytic T cell hybrid FLH 1.25.5, IL-l-sensitive LBRM-33 (clone 1A5) T lymphoma, macrophage tumor cells (P388D1, J771-D4, WEHI-3), surface Ig + B lymphomas (BCL1, WEHI-279, A20.2J), fibroblast cell lines (NIH3T3, L929), purified spleen T cells, Con A-activated splenocytes, an enriched population of normal IgM ÷ B lymphocytes from spleen, and LPS-activated splenocytes. In all cases, cells that had the CC11 antigen were also positive for the CB5 antigen, and the reverse, CB5-cells did not express CC11 antigen. Fig. 1 shows some examples to illustrate these results.
Tissue Distribution. We studied the presence of CCll + and CB5 ÷ cells in various tissues from normal mice by immunofluorescence staining and either microscopy or flow cytometry analysis. ~47-53% (n = 3) nucleated cells from fetal liver (14th day of gestation) of BALB/c mice, 61-79% (n = 7) nucleated bone marrow cells from 6-8-wk-old (CBA/J, BALB/c) mice, but only 3-10% (n = 3) splenocytes from young adult BALB/c mice were positive for both CC11 and CB5 antigens. Thymus, lymph node, heart, and kidney from young adult mice were negative (~< 1%).
Biochemical Characterization. The CC11 mAb precipitates from surface 125I-labelled 1L-3-dependent clones a protein that runs as a very diffuse band with an Mr of 50,000-70,000 under reducing conditions as determined by SDS-PAGE (Fig. 2a, lane A) . Depending upon exposure time, the band resolved into two diffuse species (Fig. 2b, lane A) , which were also present in the alkylated sample under nonreducing conditions (not shown). CC 11 mAb did not precipitate similar species from radioactively labelled control EL-4 cells (Fig. 2a, lane F and b , lane E). The 75,000 Mr band present in precipitates from EL-4 ceils with CC11 mAb was not observed in all the experiments. In the instances where it was present (such as in the experiment depicted in Fig. 2 ) the band showed a very different mobility before and after deglycosylation, and had a different pI than the antigen precipitated from both IL-3-dependent clones and freshly isolated bone marrow cells (Fig. 2, a and b, and other data not shown) . Furthermore, in immunoprecipitations from the same labelled EL-4 cells with mAb of different specificity than that of CC11/CB5 mAb, a similar 75,000 Mr band was observed again in some but not all the experiments. Thus, it was not specifically precipitated by CC 11 and CB5. Rather, it coprecipitated nonspecifically from labelled EL-4 cells under the conditions studied. Accordingly, the CC11/CB5 glycoprotein was not detected (four separate experiments) on the cell membrane of the same EL-4 cells, as determined by immunofluorescence and flow fluorometry analysis (Fig.  1, i) .
The other control for the specificity of the molecule precipitated by CC 11 was that M1/42 anti-H-2 precipitated from IL-3-dependent Bc/Bm 11 cells proteins with Mr compatible with that of H-2 antigens, but incompatible with that detected by CC11 or CB5 (data not shown). The CC 1 1 molecules from different cell populations show slightly different mobilities in SDS-PAGE, depending on the origin of the cells (Fig. 2a) . Thus, the CC 1 1 molecule of freshly isolated bone marrow cells often showed a slightly l o w e r m o b i l i t y t h a n the CC11 p r o t e i n o f I L -3 -d e p e n d e n t clones (Fig. 2 a , lane  C) . Likewise, the CC 11 m o l e c u l e o f A b e i s o n v i r u s -t r a n s f o r m e d pre-B l y m p h o m a s (Raw8. I, Bc-! 6) has similar mobilities to that o f I L -3 -d e p e n d e n t clones a n d b o n e m a r r o w cells, b u t the l o w e r Mr species o f the m o l e c u l e a r e n o t p r e s e n t in these cells (Fig. 2 a , lanes D a n d E) . Such h e t e r o g e n e i t y in size o f the CC11 m o l e c u l e seems to b e d u e m a i n l y to d i f f e r e n c e s in glycosylation. I n d e e d , t r e a t m e n t o f the C C I I a n t i g e n o f e i t h e r I L - with endoglycosidase F yields a band of M, ~40,000, and a doublet at 30,000 and 28,000 on both types of cells, probably representing partially and totally deglycosylated material, respectively (Fig. 2b, lanes B and D) . Two-dimensional electrophoresis shows that the CC11 antigen of either IL-3-dependent Bc/Bm 11 cells (Fig. 2c) or bone marrow cells (Fig. 2d) focuses between pH 5.7 and 6.2, which is accompanied by four weak bands at a lower molecular weight of pH 7.0-8.0, probably reflecting different degrees of sialylation.
The molecules recognized by CCll and CB5 are identical by SDS-PAGE analysis on all cells tested.
Functional Relationship to the Action of lL-3. The possible functional relationship between the CC 11/CB5 glycoprotein and the action of I L-3 was investigated in three different ways. First, we tested the effect of mAb CC 11 and CB5 on the growth of cloned cell lines supported by IL-3. CC 11 inhibited the proliferative response promoted by IL-3.2 #g/ml of the antibody inhibited by -60-70% the proliferation of Bc/Bm 11 cells supported by 10 U/ml of rIL-3 (Fig. 3) . This inhibitory effect was greater if lower concentrations were used, and could be overcome by higher concentrations of the growth factor (Fig. 3) . mAb CB5 exbibited less inhibitory activity than CC11 (Fig. 3 and Table I ). The antibodies interfered with the action of IL-3 on different IL-3-sensitive cell lines obtained from various tissues (fetal liver, bone marrow, spleen) and derived from different strains of mice. The inhibition of IL-3-driven growth caused by mAb CC11 and CB5 is specific, mAb against other antigens present on the cell membrane of the same target cells (eg. H-2, B-220) did not affect their growth supported by IL-3 (Fig. 3) . Moreover, neither CC11 nor CB5 showed inhibitory or stimulatory effects on the action of IL-2, purified IL-1, or B cell maturation factor (BMF); nor on the proliferative responses of splenocytes initiated by Con A, PWM, and LPS; nor on the maturation of spleen B cells into antibody-secreting cells stimulated by LPS (Table I) CC11 and CB5 mAb were tested for their activity on the action of purified IL-1 (20 U/ml), rIL-2 (20 U/ml), rlL-3 (10 U/ml), BMF (final concentration, 10%); proliferative responses of spleen cells to Con A (2 ug/ml), PWM (1 #g/ml), LPS (50 #g/rnl); and in the maturation of splenic B cells into antibody-secreting cells stimulated by LPS. Data are expressed as Acpm (cpm in stimulated cultures -cpm unstimulated cultures) for the proliferative responses, and as IgM PFC per culture for the antibody-production responses.
by CC11 and CB5. The IL-3-dependent Bc/Bm 11 cells were preincubated in rIL-3 at 37°C for 6-8 h. The same cells were also preincubated in rIL-2 or purified GM-CSF and served as controls. The cells were then assessed for the presence of CB5, CC11, and class I MHC (control) antigens by immunofluorescence staining and flow cytometry. The results (Fig. 4) showed that Bc/Bm 1 I cells preincubated in IL-3 bound significantly less CC11 and CB5 than the cells preincubated in medium only (Fig. 4, a and b) . IL-3 did not, however, affect the expression of class I MHC antigens on the cells (Fig. 4 b) . Nor did GM-CSF (Fig.  4 c) or I L-2 (Fig. 4 d) modulate the expression of the CC 11/CB5 glycoprotein on the cells. Thus, IL-3 specifically modulates the expression of the CC11/CB5 glycoprotein on the cell membrane. Third, freshly isolated bone marrow cells were separated into cells having (CC 11 +) and cells lacking (CC 11-) the CC 11 glycoprotein on their cell membrane, as detailed in Materials and Methods. After an incubation period at 37°C to allow both shedding of the antibody and reexpression of the CC11/CB5 glycoprotein, CC11 ÷ and CC11-cell populations were tested for their proliferative response to IL-3 and to other cytokines as well. The results, obtained in an experiment where we could obtain highly purified CC11 + (>~98.7% CC11/CB5 + cells) and CC 11-(~< 1% CC 11/CB5 ÷ cells) cell populations are depicted in Fig. 5 . While CC 11 + cells proliferated in response to IL-3 CC 11-cells did not. Neither cell population showed significant responses to purified IL-1 or rIL-2, but both CC 11 + and CC 11-cells proliferated in response to a crude supernatant containing various activities released by mouse spleen cells stimulated by Con A (ConASup). Similar results were obtained when bone marrow cells were separated into The alternative explanation for the observations described here is that the CC11/CB5 glycoprotein might not be the IL-3R per se, but it might be related to it. Although we cannot directly exclude this possibility, it seems to us less likely because one needs to further imply that the CC11/CB5 glycoprotein is linked to IL-3-R on the cell membrane (to explain its specific modulation by IL-3), and that it plays specifically a crucial role in the action of IL-3. We expect that, by isolating the gene encoding the CCll/CB5 glycoprotein, and using subsequent gene transfer experiments, we will be able to directly distinguish between these possibilities. In any event, it is clear that the CC 11 and CB5 mAb specifically react against IL-3-sensitive normal mouse cells, and that the glycoprotein detected by them plays an essential role in the action of IL-3.
The CC11/CB5 molecule has an Mr of 50,000-70,000 by SDS-PAGE, and a pI of 5.7-6.2. The same species were observed under reducing and nonreducing conditions, excluding the presence o£ disulfide links between them. There is heterogeneity in size of the CC 11/CB5 glycoprotein expressed on I L-3-dependent clones, bone marrow cells, and pre-B cell lymphomas. This is due mainly to differences in glycosylation. Treatment of the CC 11/CB5 molecule with endoglycosidase F yields bands of Mr 40,000, 30,000, and 28,000 from material obtained from both IL-3-dependent clones and bone marrow cells. The different species probably represent partially and totally deaminoglycosylated material, respectively, or alternatively, might indicate the presence of two proteins. The data are most compatible with the view that the CC 11/CB5 molecule is made of a single chain protein of 28,000 Mr, carrying heterogeneous N-linked glycans of high relative molecular weight. Nevertheless, at present we cannot exclude the possibility that this molecule is made of two chain proteins of different size. Further biochemical studies will hopefully distinguish between these possibilities. The heterogeneity in size of the CCll/CB5 glycoprotein of different cell populations is not a unique feature of this molecule. It is known that the same polypeptide can be glycosylated differently in different cell types (24) . For example, receptors for several iigands (eg. C3, Fc, IL-2) have been found (25) (26) (27) to exhibit heterogeneity due mainly to differences in glycosylation.
Interestingly, pre-B cell lymphomas (18.81, Raw 8.1, Bcl6) express the CC 11/CB5 glycoprotein on their cell membrane. These results, and the findings that purified CC11/CB5 + bone marrow cells contain B cell precursors (surface Ig-negative) that proliferate and give rise in vitro to antibody-secreting cells after LPS stimulation (R. Palacios, manuscript in preparation) are consistent with the proposition that IL-3 acts on a population of mouse B cell precursors (9, 10) . Studies are in progress to determine whether bone marrow cells committed to the T cell lineage express the CC11/CB5 glycoprotein. Thymocytes from fetal and adult thymuses have neither detectable CCI 1/CB5 antigens, nor do they use IL-3 as growth factor (R. Palacios unpublished results).
Freshly isolated nucleated cells from fetal liver and bone marrow cells have CC11/CB5 antigen, and proliferate in response to IL-3, suggesting that these cells may be using IL-3 in vivo. Mature T cells are known to synthesize IL3 (28) , but these cells are not present in fetal liver, nor are they easily detectable in young adult T cell-deficient nu/nu mice. Yet these mice have normal (in bone marrow) and increased (in spleen) numbers of CC11/CB5 + cells as compared to euthymic mice, and both tissues contain cells that grow in IL-3 (R. Palacios, unpublished results). These observations raise the question what cells normally make IL-3 in fetal liver and bone marrow.
Finally, it is worth stressing that the CC11/CB5 glycoprotein is expressed not only on normal cells but also on their tumor counterparts. There is accumulating evidence that some oncogenes code for molecules resembling growth factors, their receptors, or molecules involved in the transduction of signals delivered by growth factors (29, 30) . Possibly the CC11/CB5 protein is encoded by a protooncogene involved in transformation of haematopoietic ceils. Our initial survey excluded the products of the src, ras, abl, erb-B, mos, sis, fes, Myc, Myb, fos, and fms as candidates, based on biochemical criteria and cellular location.
Summary
The mAb CCll and CB5 reacted against all 18 IL-3-dependent cell lines tested, but not against cells insensitive to IL-3. Up to 53% nucleated cells from fetal liver (14th day of gestation) and 79% bone marrow cells of young adult mice were positive for both CC11 and CB5 antigens, but cells from thymus, lymph node, heart, and kidney were negative. The molecule recognized by both antibodies has an Mr of 50,000-70,000, a pI of 5.7-6.2, and carries heterogeneous N-linked glycans of high 11,/,-. Both CC11 and CB5 specifically inhibited the growth of clones supported by rIL-3. Neither antibody affected the action of IL-I, IL-2, or B cell maturation factor; the proliferative responses of splenocytes to Con A, PWM, and LPS; nor the maturation of spleen B cells into antibody-secreting cells stimulated by LPS. rIL-3 specifically modulated the expression of the CC 11/CB5 glycoprotein on the cell membrane of IL-3-dependent clones. Finally, freshly isolated bone marrow cells that have the CC11/CB5 glycoprotein on the cell membrane proliferated in response to IL-3, whereas cells that lack this molecule did not. We suggest that CC11 and CB5 react against receptors for mouse IL-3.
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